Fonar Corporation Reports 6% Revenue Increase and 37% EPS Growth in Q3 Fiscal 2025; Net Income Rises 25%

Reuters
05-15
Fonar Corporation Reports 6% Revenue Increase and 37% EPS Growth in Q3 Fiscal 2025; Net Income Rises 25%

Fonar Corporation announced its financial results for the third quarter of fiscal 2025, revealing a 6% increase in Total Revenues-Net to $27.2 million for the quarter ended March 31, 2025, compared to $25.7 million in the same quarter of the previous year. Net Income saw a notable rise of 25%, reaching $3.1 million for the quarter, up from $2.48 million the year before. Additionally, Diluted Net Income Per Common Share Available to Common Stockholders increased by 37% to $0.37 per share from $0.27 per share in the prior year's quarter. Income from Operations experienced a slight decrease of 2%, totaling $3.7 million compared to $3.8 million in the corresponding quarter of the previous year. The company also reported a decrease in Total Cash, Cash Equivalents, and Short-Term Investments by 4%, standing at $54.4 million as of March 31, 2025, down from $56.67 million as of June 30, 2024. Fonar's diagnostic imaging management subsidiary, Health Management Company of America $(HMCA.UK)$, set a new company record by completing 54,612 MRI scans in the third quarter, marking a 2.8% increase from the previous quarter and a 3.4% increase compared to the same quarter in fiscal 2024. Over the nine-month period, HMCA achieved a record 160,780 MRI scans, a 3.9% rise from 154,790 scans in the corresponding period of the previous year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fonar Corporation published the original content used to generate this news brief via Newsfile (Ref. ID: 252182) on May 15, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10